These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 27471402)

  • 21. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
    Fass R; Inadomi J; Han C; Mody R; O'Neil J; Perez MC
    Clin Gastroenterol Hepatol; 2012 Mar; 10(3):247-53. PubMed ID: 22155561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
    Peura DA; Pilmer B; Hunt B; Mody R; Perez MC
    Aliment Pharmacol Ther; 2013 Apr; 37(8):810-8. PubMed ID: 23451835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial.
    Chiang HH; Wu DC; Hsu PI; Kuo CH; Tai WC; Yang SC; Wu KL; Yao CC; Tsai CE; Liang CM; Wang YK; Wang JW; Huang CF; Chuah SK;
    Drug Des Devel Ther; 2019; 13():1347-1356. PubMed ID: 31118571
    [No Abstract]   [Full Text] [Related]  

  • 24. Dexlansoprazole for Heartburn Relief in Adolescents with Symptomatic, Nonerosive Gastro-esophageal Reflux Disease.
    Gold BD; Pilmer B; Kierkuś J; Hunt B; Perez MC; Gremse D
    Dig Dis Sci; 2017 Nov; 62(11):3059-3068. PubMed ID: 28916953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of gastroesophageal reflux disease: two new oral formulations dexlansoprazole MR and esomezol (esomeprazole strontium).
    Parekh PJ; Oldfield EC; Johnson DA
    Expert Opin Pharmacother; 2014 Jun; 15(9):1215-22. PubMed ID: 24749891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor.
    Lee RD; Mulford D; Wu J; Atkinson SN
    Aliment Pharmacol Ther; 2010 May; 31(9):1001-11. PubMed ID: 20180789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor--evidence for dosing flexibility.
    Lee RD; Vakily M; Mulford D; Wu J; Atkinson SN
    Aliment Pharmacol Ther; 2009 Apr; 29(8):824-33. PubMed ID: 19243357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease.
    Liang CM; Kuo MT; Hsu PI; Kuo CH; Tai WC; Yang SC; Wu KL; Wang HM; Yao CC; Tsai CE; Wang YK; Wang JW; Huang CF; Wu DC; Chuah SK;
    World J Gastroenterol; 2017 Dec; 23(47):8395-8404. PubMed ID: 29307999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
    Vakily M; Lee RD; Wu J; Gunawardhana L; Mulford D
    Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 4 Study in Patients From Asia With Gastroesophageal Reflux Disease Treated With Dexlansoprazole.
    Wu JCY; Sheu BS; Wu MS; Lee YC; Choi MG
    J Neurogastroenterol Motil; 2020 Jan; 26(1):85-95. PubMed ID: 31597230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dexlansoprazole MR.
    Aslam N; Wright R
    Expert Opin Pharmacother; 2009 Oct; 10(14):2329-36. PubMed ID: 19708852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease.
    Fiedorek S; Tolia V; Gold BD; Huang B; Stolle J; Lee C; Gremse D
    J Pediatr Gastroenterol Nutr; 2005 Mar; 40(3):319-27. PubMed ID: 15735486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
    Peura DA; Pilmer B; Hunt B; Mody R; Perez MC
    Aliment Pharmacol Ther; 2013 Nov; 38(10):1303-11. PubMed ID: 24118079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Pilot Randomized Controlled Study of Dexlansoprazole MR-Based Triple Therapy for Helicobacter Pylori Infection.
    Wu DC; Kuo CH; Tsay FW; Hsu WH; Chen A; Hsu PI
    Medicine (Baltimore); 2016 Mar; 95(11):e2698. PubMed ID: 26986096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nocturnal acid breakthrough and esophageal acidification during treatment with dexlansoprazole as compared to omeprazole in patients with gastroesophageal reflux disease.
    Ghoshal UC; Blaachandran A; Rai S; Misra A
    Indian J Gastroenterol; 2022 Aug; 41(4):405-414. PubMed ID: 35771390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dexlansoprazole is Effective in Relieving Heartburn during the Fasting Month of Ramadan.
    Rimmani HH; Rustom LBO; Rahal MA; Shayto RH; Chaar H; Sharara AI
    Dig Dis; 2019; 37(3):188-193. PubMed ID: 30625462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease.
    Kukulka M; Nudurupati S; Perez MC
    Clin Exp Gastroenterol; 2014; 7():461-71. PubMed ID: 25525378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
    Peura DA; Metz DC; Dabholkar AH; Paris MM; Yu P; Atkinson SN
    Aliment Pharmacol Ther; 2009 Nov; 30(10):1010-21. PubMed ID: 19735233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Indirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastro-oesophageal reflux disease.
    Wu MS; Tan SC; Xiong T
    Aliment Pharmacol Ther; 2013 Jul; 38(2):190-201. PubMed ID: 23718547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
    Armstrong D; Paré P; Pericak D; Pyzyk M;
    Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.